Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication

References

• CDC. History of polio. Global immunization. 2021 [accessed 2022 Mar 4]. https://www.cdc.gov/polio/what-is-polio/index.htm#:~:text=Polio%2C%20or%20poliomyelitis%2C%20is%20a,move%20parts%20of%20the%20body.
   Google Scholar
• Racaniello VR. One hundred years of poliovirus pathogenesis. Virology. 2006;344(1):9–24. doi:10.1016/j.virol.2005.09.015.
   PubMed Web of Science ®Google Scholar
• Minor P. The polio endgame. Hum Vaccin Immunother. 2014;10(7):2106–08. doi:10.4161/21645515.2014.981115.
   PubMedGoogle Scholar
• Hart CW. Franklin Delano Roosevelt: a famous patient. J Relig Health. 2014;53(4):1102–11. doi:10.1007/s10943-014-9886-3.
   PubMed Web of Science ®Google Scholar
• Minor PD. Poliovirus biology. Structure. 1996;4(7):775–78. doi:10.1016/s0969-2126(96)00084-6.
   PubMed Web of Science ®Google Scholar
• Le Bouvier GL. Poliovirus D and C antigens: their differentiation and measurement by precipitation in agar. Br J Exp Pathol. 1959;40:452–63.
   PubMedGoogle Scholar
• Le Bouvier GL. The D to C change in poliovirus particles. Br J Exp Pathol. 1959;40:605–20.
   PubMedGoogle Scholar
• Ferguson M, Wood DJ, Minor PD. Antigenic structure of poliovirus in inactivated vaccines. J Gen Virol. 1993;73:685–90. doi:10.1099/0022-1317-74-4-685.
   Google Scholar
• CDC. Our progress against polio. 2021. [accessed 2022 Mar 8]. https://www.cdc.gov/polio/progress/index.htm.
   Google Scholar
• Polio Golbal Eradication Initiative. [accessed 2022 Mar 11]. https://polioeradication.org/polio-today/history-of-polio/.
   Google Scholar
• Dattani S, Spooner F, Ochmann S, Polio RM. Our world in data. 2022 [accessed 2022 Jul 25]. https://ourworldindata.org/polio.
   Google Scholar
• Khullar D The preventable tragedy of polio in New York. The New Yorker. 2022 [accessed 2022 Sept 1]. https://www.newyorker.com/news/daily-comment/the-preventable-tragedy-of-polio-in-new-york.
   Google Scholar
• Bandyopadhyay AS, Garon J, Seib K, Orenstein WA. Polio vaccination: past, present and future. Future Microbiol. 2015;10(5):791–808. doi:10.2217/fmb.15.19.
   PubMed Web of Science ®Google Scholar
• Modlin JF, Bandyopadhyay AS, Sutter R. Immunization against poliomyelitis and the challenges to worldwide poliomyelitis eradication. J Infect Dis. 2021;224(12 Suppl 2):S398–404. doi:10.1093/infdis/jiaa622.
   PubMedGoogle Scholar
• WHO. Eupolio Inj. [accessed 2022 Mar 3]. https://extranet.who.int/pqweb/content/eupolio-inj.
   Google Scholar
• Konopka-Anstadt JL, Campagnoli R, Vincent A, Shaw J, Wei L, Wynn NT, Smithee SE, Bujaki E, Te Yeh M, Laassri M, et al. Development of a new oral poliovirus vaccine for the eradication end game using codon deoptimization. NPJ Vaccines. 2020;5(1):26. doi:10.1038/s41541-020-0176-7.
   PubMed Web of Science ®Google Scholar
• Vidor E. Poliovirus Vaccine–Inactivated. In: Plotkin SA, Orenstein WA, Offit, PA, Edwards, KM, editors. Plotkin’s Vaccines. 7th Edition. United States of America: Elsevier 9780323393010; 2018.
   Google Scholar
• Offit PA. The cutter incident, 50 years later. N Engl J Med. 2005;352(14):1411–12. doi:10.1056/NEJMp048180.
   PubMed Web of Science ®Google Scholar
• Fitzpatrick M. The cutter incident: how america’s first polio vaccine led to a growing vaccine crisis. J R Soc Med. 2006;99(3):156. doi:10.1177/014107680609900320.
   Google Scholar
• Connor RI, Brickley EB, Wieland-Alter WF, Ackerman ME, Weiner JA, Modlin JF, Bandyopadhyay AS, Wright PF. Mucosal immunity to poliovirus. Mucosal Immunity. 2022;15:1–9. doi:10.1038/s41385-021-00428-0.
   PubMed Web of Science ®Google Scholar
• Hird TR, Grassly NC. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog. 2012;8(4):e1002599. doi:10.1371/journal.ppat.1002599.
   PubMed Web of Science ®Google Scholar
• Yuhong Xiao HD, Daniell H. Long-term evaluation of mucosal and systemic immunity and protection conferred by different polio booster vaccines. Vaccine. 2017;35:5418–25. doi:10.1016/2Fj.vaccine.2016.12.061.
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay AS, Orenstein WA. Evolution of inactivated poliovirus vaccine use for the endgame and beyond. J Infect Dis. 2020;221(6):861–63. doi:10.1093/infdis/jiz300.
   PubMed Web of Science ®Google Scholar
• Marita Zimmermann BH, Lyons H. Projection of costs of polio eradication compared to permanent control. J Infect Dis. 2020;561–65. doi:10.1093/infdis/jiz488.
   PubMed Web of Science ®Google Scholar
• Bakker WA, Thomassen YE, van’t Oever AG, Westdijk J, van Oijen MG, Sundermann LC, van’t Veld P, Sleeman E, van Nimwegen FW, Hamidi A, et al. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV. Vaccine. 2011;29(41):7188–96. doi:10.1016/j.vaccine.2011.05.079.
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay AS, Singh H, Fournier-Caruana J, Modlin JF, Wenger J, Partridge J, Sutter RW, Zaffran MJ. Facility-associated release of polioviruses into communities—risks for the posteradication era. Emerg Infect Dis. 2019;25(7):1363–69. doi:10.3201/2Feid2507.181703.
   PubMed Web of Science ®Google Scholar
• WHO. Containment verification of large-scale polio vaccine production and quality control facilities following the interruption of endemic poliomyelitis transmission. 2003 [accessed 2022 Mar 8]. https://cdn.who.int/media/docs/default-source/biologicals/vaccine-quality/polio-vaccine-containment-meeting-reportf0e0079f-4e5f-4fcb-b9df-2867937cec1d.pdf?sfvrsn=837d3772_1&download=true#:~:text=Currently%20Sabin%20strains%20used%20for,(BSL%2D1)%20conditions.
   Google Scholar
• Wan Y, Hickey JM, Bird C, Witham K, Fahey P, Forster A, Joshi SB, Volkin DB. Development of stabilizing formulations of a trivalent inactivated poliovirus vaccine in a dried state for delivery in the nanopatch microprojection array. J Pharm Sci. 2018;107(6):1540–51. doi:10.1016/j.xphs.2018.01.027.
   PubMed Web of Science ®Google Scholar
• Shimizu H. Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan. Vaccine. 2016;34(16):1975–85. doi:10.1016/j.vaccine.2014.11.015.
   PubMed Web of Science ®Google Scholar
• Burke CJ, Hsu TA, Volkin DB. Formulation, stability, and delivery of live attenuated vaccines for human use. Crit Rev Ther Drug Carrier Syst. 1999;16(1):1–83. doi:10.1615/CritRevTherDrugCarrierSyst.v16.i1.10.
   PubMed Web of Science ®Google Scholar
• Verheyden B, Andries K, Rombaut B. Capsid and RNA stabilisation of the oral polio vaccine. Vaccine. 2001;19(15):1899–905. doi:10.1016/S0264-410X(00)00442-4.
   PubMed Web of Science ®Google Scholar
• Chen CH, Wu R, Roth LG, Guillot S, Crainic R. Elucidating mechanisms of thermostabilization of poliovirus by D2O and MgCl2. Arch Biochem Biophys. 1997;342(1):108–16. doi:10.1006/abbi.1997.0111.
   PubMed Web of Science ®Google Scholar
• Newman JF, Tirrell S, Ullman C, Piatti PG, Brown F. Stabilising oral polio vaccine at high ambient temperatures. Vaccine. 1995;13(15):1431–35. doi:10.1016/0264-410X(95)00070-H.
   PubMedGoogle Scholar
• Wilton T, Dunn G, Eastwood D, Minor PD, Martin J. Effect of formaldehyde inactivation on poliovirus. J Virol. 2014;88(20):11955–64. doi:10.1128/JVI.01809-14.
   PubMed Web of Science ®Google Scholar
• Wilton T. Methods for the quality control of inactivated poliovirus vaccines. Methods Mol Biol. 2016;1387:279–97. doi:10.1007/978-1-4939-3292-4_15.
   PubMedGoogle Scholar
• Kersten G, Hazendonk T, Beuvery C. Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains. Vaccine. 1999;17(15–16):2059–66. doi:10.1016/s0264-410x(98)00409-5.
   PubMed Web of Science ®Google Scholar
• Arita M, Iwai-Itamochi M. High-throughput analysis of anti-poliovirus neutralization antibody titre in human serum by the pseudovirus neutralization test. Sci Rep. 2022;12(1):16074. doi:10.1038/s41598-022-20544-6.
   PubMed Web of Science ®Google Scholar
• Wood DJ, Health AB, Sawyer LA. A WHO collaborative study on assays of the antigenic content of inactivated poliovirus vaccines. Biologicals. 1995;23:83–94. doi:10.1016/1045-1056(95)90017-9.
   PubMed Web of Science ®Google Scholar
• Wood DJ, Heath AB. A WHO collaborative study of immunogenicity assays of inactivated poliovirus vaccines. Biologicals. 1995;23:301–11. doi:10.1006/biol.1995.0049.
   PubMed Web of Science ®Google Scholar
• Murakami K, Fujii Y, Someya Y. Effects of the thermal denaturation of Sabin-derived inactivated polio vaccines on the D-antigenicity and the immunogenicity in rats. Vaccine. 2020;38(17):3295–99. doi:10.1016/j.vaccine.2020.03.027.
   PubMed Web of Science ®Google Scholar
• White JA, Estrada M, Weldon WC, Chumakov K, Kouiavskaia D, Fournier-Caruana J, Stevens E, Gary HE Jr., Maes EF, Oberste MS, et al. Assessing the potency and immunogenicity of inactivated poliovirus vaccine after exposure to freezing temperatures. Biologicals. 2018;53:30–38. doi:10.1016/j.biologicals.2018.03.002.
   PubMed Web of Science ®Google Scholar
• Hasija M, Li L, Rahman N, Ausar SF. Forced degradation studies: an essential tool for the formulation development of vaccines. Vaccine Dev Ther. 2013;3:11–33. doi:10.2147/VDT.S41998.
   Google Scholar
• Markova N, Cairns S, Jankevics-Jones H, Kaszuba M, Caputo F, Parot J. Biophysical characterization of viral and lipid-based vectors for vaccines and therapeutics with light scattering and calorimetric techniques. Vaccines. 2021;10:49. doi:10.3390/vaccines10010049.
   Web of Science ®Google Scholar
• Krell T, Manin C, Nicolaï MC, Pierre-Justin C, Bérard Y, Brass O, Gérentes L, Leung-Tack P, Chevalier M. Characterization of different strains of poliovirus and influenza virus by differential scanning calorimetry. Biotechnol Appl Biochem. 2005;41(Pt 3):241–46. doi:10.1042/ba20040113.
   PubMedGoogle Scholar
• Qi W, Zeng Y, Orgel S, Francon A, Kim JH, Randolph TW, Carpenter JF, Middaugh CR. Preformulation study of highly purified inactivated polio vaccine, serotype 3. J Pharm Sci. 2014;103(1):140–51. doi:10.1002/jps.23801.
   PubMed Web of Science ®Google Scholar
• Torisu T, Shikama S, Nakamura K, Enomoto K, Maruno T, Mori A, Uchiyama S, Satou T. Physicochemical characterization of sabin inactivated poliovirus vaccine for process development. J Pharm Sci. 2021;110(5):2121–29. doi:10.1016/j.xphs.2020.12.012.
   PubMed Web of Science ®Google Scholar
• Huijuan Y, Xiaohu D, Ze L, Wei C, Jian Z, Lei M, Shaohui S, Weidong L, Guoyang L. Role of phenol red in the stabilization of the Sabin type 2 inactivated polio vaccine at various pH values. J Med Virol. 2019;91(1):22–30. doi:10.1002/jmv.25289.
   PubMed Web of Science ®Google Scholar
• Cai W, Ping L, Shen W, Liu J, Zhang M, Zhou J, Peng J, Wang M, Zhu Y, Ji G, et al. Potency of the Sabin inactivated poliovirus vaccine (sIPV) after exposure to freezing temperatures in cold chains. Hum Vaccines Immunother. 2020;16(8):1866–74. doi:10.1080/21645515.2019.1709352.
   PubMed Web of Science ®Google Scholar
• Westdijk J, Kogelman A, van der Put R, Eksteen Z, Suarez D, Kersten GFA, Metz B, Danial M. Immunochemical and biophysical characterization of inactivated Sabin poliovirus products: insights into rapid quality assessment tools. J Pharm Sci. 2022;111(4):1058–69. doi:10.1016/j.xphs.2022.01.031.
   PubMed Web of Science ®Google Scholar
• WHO. List of prequalified vaccines. [accessed 2022 Jul 25]. https://extranet.who.int/pqweb/vaccines/list-prequalified-vaccines.
   Google Scholar
• PATH. Summary of stability data for licensed vaccines. [accessed 2022 Jul 25]. https://media.path.org/documents/TS_vaccine_stability_table.pdf?_gl=1*i2rxs2*_ga*MTIwMjY1MjY4MS4xNjU4Nzg1NzM4*_ga_YBSE7ZKDQM*MTY1ODc4NTczNy4xLjAuMTY1ODc4NTczOS4w.
   Google Scholar
• US-FDA. Vaccines licensed for use in the United States. [accessed 2022 Jul 25]. https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states.
   Google Scholar
• WHO. Picovax. 2021 [accessed 2022 Sept 5]. https://extranet.who.int/pqweb/content/picovax.
   Google Scholar
• Jerajani K, Wan Y, Kumru OS, Pllagurla SP, Kumar P, Sharma N, Ogun O, Mapari S, Brendle S, Christensen ND, et al. Multi-dose formulation development for a quadrivalent human papillomavirus virus-like particle-based vaccine: part I- screening of preservative combinations. J Pharm Sci. 2022;111(11):2983–97. doi:10.1016/j.xphs.2022.07.019.
   PubMed Web of Science ®Google Scholar
• Moynihan M, Petersen I. The durability of inactivated poliovirus vaccine: studies on the stability of potency in vivo and in vitro. J Biol Stand. 1982;10(3):261–68. doi:10.1016/s0092-1157(82)80027-9.
   PubMedGoogle Scholar
• Kristensen D Summary of stability data for licensed vaccines. PATH. [accessed 2012 Mar 11]. https://path.azureedge.net/media/documents/TS_vaccine_stability_table.pdf.
   Google Scholar
• Hamidi A, Bakker WAM. Innovative IPV from attenuated Sabin poliovirus or newly designed alternative seed strains. Pharm Pat Anal. 2012;5:589–99. doi:10.4155/ppa.12.70.
   Google Scholar
• Plotkin S, Robinson JM, Cunningham G, Iqbal R, Larsen S. The complexity and cost of vaccine manufacturing – an overview. Vaccine. 2017;35(33):4064–71. doi:10.1016/j.vaccine.2017.06.003.
   PubMed Web of Science ®Google Scholar
• Lee BY, Norman BA, Assi TM, Chen SI, Bailey RR, Rajgopal J, Brown ST, Wiringa AE, Burke DS. Single versus multi-dose vaccine vials: an economic computational model. Vaccine. 2010;28(32):5292–300. doi:10.1016/j.vaccine.2010.05.048.
   PubMed Web of Science ®Google Scholar
• Thomassen YE, van ‘T Oever AG, van Oijen MG, Wijffels RH, van der Pol LA, Bakker WA. Next generation inactivated polio vaccine manufacturing to support post polio-eradication biosafety goals. PLoS One. 2013;8(12):e83374. doi:10.1371/journal.pone.0083374.
   PubMed Web of Science ®Google Scholar
• WHO. WHO policy statement: Multi-Dose Vial Policy (MDVP). 2014 [accessed 2022 Sept 1]. https://apps.who.int/iris/bitstream/handle/10665/135972/WHO_IVB_14.07_eng.pdf.
   Google Scholar
• Sawyer LA, McInnis J, Patel A, Horne AD, Albrecht P. Deleterious effect of thimerosal on the potency of inactivated poliovirus vaccine. Vaccine. 1994;12(9):851–56. doi:10.1016/0264-410x(94)90296-8.
   PubMed Web of Science ®Google Scholar
• Davisson EO, Powell HM, Macfarlane JO, Hodgson R, Stone RL, Culbertson CG. The preservation of poliomyelitis vaccine with stabilized merthiolate. J Lab Clin Med. 1956;47:8–19.
   PubMed Web of Science ®Google Scholar
• Kraan H, ten Have R, van der Maas L, Kersten G, Amorij J-P. Incompatibility of lyophilized inactivated polio vaccine with liquid pentavalent whole-cell-pertussis-containing vaccine. Vaccine. 2016;34(38):4572–78. doi:10.1016/j.vaccine.2016.07.030.
   PubMed Web of Science ®Google Scholar
• Alghounaim M, Alsaffar Z, Alfraij A, Bin-Hasan S, Hussain E. Whole-cell and acellular pertussis vaccine: reflections on efficacy. Med Princ Pract. 2022;31(4):313–21. doi:10.1159/000525468.
   PubMed Web of Science ®Google Scholar
• Sawant N, Kaur K, Holland DA, Hickey JM, Agarwal S, Brady JR, Dalvie NC, Tracey MK, Velez-Suberbie ML, Morris SA, et al. Rapid Developability assessments to formulate recombinant protein antigens as stable, low-cost, multi-dose vaccine candidates: case-study with Non-Replicating Rotavirus (NRRV) vaccine antigens. J Pharm Sci. 2021;110:1042–53. doi:10.1016/j.xphs.2020.11.039.
   PubMed Web of Science ®Google Scholar
• Kaur K, Xiong J, Sawant N, Agarwal S, Hickey JM, Holland DA, Mukhopadhyay TK, Brady JR, Dalvie NC, Tracey MK, et al. Mechanism of thimerosal-induced structural destabilization of a recombinant rotavirus P[4] protein antigen formulated as a multi-dose vaccine. J Pharm Sci. 2021;110:1054–66. doi:10.1016/j.xphs.2020.11.033.
   PubMed Web of Science ®Google Scholar
• EasySix, Panacea Biotec. Package insert. [ accessed 2022 Mar 19]. https://media.panaceabiotec.com/documents/2019/7/24/Easysix-PMPIS05903.pdf.
   Google Scholar
• Kumar R, Sharma IJ, Vyankatrao SA, Manohar D, Sharma HJ; An immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation there of. PCT/IB2018/055180. 2019. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019016654.
   Google Scholar
• Young CS, Ae NY, Ji KE; Combination vaccine composition for multiple-dosage. PCT/KR2016/010313. 2017. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2017048038.
   Google Scholar
• Mangarule S, Palkar S, Mitra M, Ravi MD, Dubey AP, Moureau A, Jayanth MV, Patel DM, Ravinuthala S, Jagga SR, et al. Safety and immunogenicity of a hexavalent DTwP-IPV-HB-PRP~ T vaccine versus separate DTwP-HB-PRP~ T and IPV vaccines in healthy infants in India. Vaccine. 2022;X:10. doi:10.1016/j.jvacx.2021.100137.
   Google Scholar
• Kumru OS, Joshi SB, Smith DE, Middaugh CR, Prusik T, Volkin DB. Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies. Biologicals. 2014;42(5):237–59. doi:10.1016/j.biologicals.2014.05.007.
   PubMed Web of Science ®Google Scholar
• Shin WJ, Hara D, Gbormittah F, Chang H, Chang BS, Jung JU. Development of thermostable lyophilized sabin inactivated poliovirus vaccine. mBio. 2018;9(6). doi:10.1128/mBio.02287-18.
   PubMed Web of Science ®Google Scholar
• Qi W, Orgel S, Francon A, Randolph TW, Carpenter JF. Urea improves stability of inactivated polio vaccine serotype 3 during lyophilization and storage in dried formulations. J Pharm Sci. 2018;107(8):2070–78. doi:10.1016/j.xphs.2018.04.019.
   PubMed Web of Science ®Google Scholar
• Kraan H, van Herpen P, Kersten G, Amorij J-P. Development of thermostable lyophilized inactivated polio vaccine. Pharm Res. 2014;31(10):2618–29. doi:10.1007/s11095-014-1359-6.
   PubMed Web of Science ®Google Scholar
• Preston KB, Randolph TW. Stability of lyophilized and spray dried vaccine formulations. Adv Drug Deliv Rev. 2021;171:50–61. doi:10.1016/j.addr.2021.01.016.
   PubMed Web of Science ®Google Scholar
• HogenEsch H, O’Hagan DT, Fox CB. Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want. NPJ Vaccines. 2018;3:51. doi:10.1038/s41541-018-0089-x.
   PubMed Web of Science ®Google Scholar
• Westdijk J, Koedam P, Barro M, Steil BP, Collin N, Vedvick TS, Bakker WA, van der Ley P, Kersten G. Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains. Vaccine. 2013;31(9):1298–304. doi:10.1016/j.vaccine.2012.12.076.
   PubMed Web of Science ®Google Scholar
• Andreasen LV, Hansen LB, Andersen P, Agger EM, Dietrich J. Aluminium hydroxide potentiates a protective Th1 biased immune response against polio virus that allows for dose sparing in mice and rats. Vaccine. 2015;33:1873–79. doi:10.1016/j.vaccine.2015.02.011.
   PubMed Web of Science ®Google Scholar
• Bravo LC, Carlos JC, Gatchalian SR, Montellano MEB, Tabora C, Thierry-Carstensen B, Tingskov PN, Sorensen C, Wachmann H, Bandyopadhyay AS, et al. Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: a phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of age. Vaccine. 2020;38(3):530–38. doi:10.1016/j.vaccine.2019.10.064.
   PubMed Web of Science ®Google Scholar
• Saez-Llorens X, Thierry-Carstensen B, Stoey LS, Sorensen C, Wachmann H, Bandyopadhyay AS, Nielsen PI, Kusk MV. Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, following vaccination in children at 2, 4, 6 and at 15-18 months. Vaccine. 2020;38(21):3780–89. doi:10.1016/j.vaccine.2020.02.066.
   PubMed Web of Science ®Google Scholar
• Wallis C, Melnick JL, Ferry GD, Wimberly IL. An aluminum marker for the differentiation and separation of virulent and attenuated polioviruses. J Exp Med. 1962;115:763–75. doi:10.1084/jem.115.4.763.
   PubMed Web of Science ®Google Scholar
• Van Ramshorst JD. The concentration of poliovirus antigens for D-antigen determination. Bull World Health Organ. 1967;36:209–18.
   PubMed Web of Science ®Google Scholar
• Hawken J, Troy SB. Adjuvants and inactivated polio vaccine: a systematic review. Vaccine. 2012;30(49):6971–79. doi:10.1016/j.vaccine.2012.09.059.
   PubMed Web of Science ®Google Scholar
• Baldwin SL, Fox CB, Pallansch MA, Coler RN, Reed SG, Friede M. Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions. Vaccine. 2011;29(4):644–49. doi:10.1016/j.vaccine.2010.11.043.
   PubMed Web of Science ®Google Scholar
• Dietrich J, Andreasen LV, Andersen P, Agger EM. Inducing dose sparing with inactivated polio virus formulated in adjuvant CAF01. PLoS One. 2014;9(6):e100879. doi:10.1371/journal.pone.0100879.
   PubMed Web of Science ®Google Scholar
• Steil BP, Jorquera P, Westdijk J, Bakker WAM, Johnston RE, Barro M. A mucosal adjuvant for the inactivated poliovirus vaccine. Vaccine. 2014;32(5):558–63. doi:10.1016/j.vaccine.2013.11.101.
   PubMed Web of Science ®Google Scholar
• Norton EB, Bauer DL, Weldon WC, Oberste MS, Lawson LB, Clements JD. The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model. Vaccine. 2015;33(16):1909–15. doi:10.1016/j.vaccine.2015.02.069.
   PubMed Web of Science ®Google Scholar
• White JA, Blum JS, Hosken NA, Marshak JO, Duncan L, Zhu CC, Norton EB, Clements JD, Koelle DM, Chen DX, et al. Serum and mucosal antibody responses to inactivated polio vaccine after sublingual immunization using a thermoresponsive gel delivery system. Hum Vaccines Immunother. 2014;10(12):3611–21. doi:10.4161/hv.32253.
   PubMed Web of Science ®Google Scholar
• Yang CT, Shi HY, Zhou J, Liang YW, Xu HL. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus. Vaccine. 2009;27(47):6558–63. doi:10.1016/j.vaccine.2009.08.047.
   PubMed Web of Science ®Google Scholar
• Ghendon Y, Markushin S, Akopova I, Koptiaeva I, Krivtsov G. Chitosan as an adjuvant for poliovaccine. J Med Virol. 2011;83(5):847–52. doi:10.1002/jmv.22030.
   PubMed Web of Science ®Google Scholar
• Ivanov AP, Dragunsky EM, Chumakov KM. 1,25-Dihydroxyvitamin D3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice. J Infect Dis. 2006;193(4):598–600. doi:10.1086/499970.
   PubMed Web of Science ®Google Scholar
• de Costa F, Yendo ACA, Cibulski SP, Fleck JD, Roehe PM, Spilki FR, Gosmann G, Fett-Neto AG. Alternative inactivated poliovirus vaccines adjuvanted with quillaja brasiliensis or quil-a saponins are equally effective in inducing specific immune responses. PLoS One. 2014;9(8):e105374. doi:10.1371/journal.pone.0105374.
   PubMed Web of Science ®Google Scholar
• Kraan H, van der Stel W, Kersten G, Amorij JP. Alternative administration routes and delivery technologies for polio vaccines. Expert Rev Vaccines. 2016;15(8):1029–40. doi:10.1586/14760584.2016.1158650.
   PubMed Web of Science ®Google Scholar
• Tzeng SY, Guarecuco R, McHugh KJ, Rose S, Rosenberg EM, Zeng YY, Langer R, Jaklenec A. Thermostabilization of inactivated polio vaccine in PLGA-based microspheres for pulsatile release. J Control Release. 2016;233:101–13. doi:10.1016/j.jconrel.2016.05.012.
   PubMed Web of Science ®Google Scholar
• Tzeng SY, McHugh KJ, Behrens AM, Rose S, Sugarman JL, Ferber S, Langer R, Jaklenec A. Stabilized single-injection inactivated polio vaccine elicits a strong neutralizing immune response. Proc Natl Acad Sci U S A. 2018;115(23):E5269–78. doi:10.1073/pnas.1720970115.
   PubMed Web of Science ®Google Scholar
• Kraan H, Soema P, Amorij JP, Kersten G. Intranasal and sublingual delivery of inactivated polio vaccine. Vaccine. 2017;35(20):2647–53. doi:10.1016/j.vaccine.2017.03.090.
   PubMed Web of Science ®Google Scholar
• Kraan H, Ploemen I, van de Wijdeven G, Que I, Löwik C, Kersten G, Amorij J-P. Alternative delivery of a thermostable inactivated polio vaccine. Vaccine. 2015;33(17):2030–37. doi:http://dx.doi.org/10.1016/j.vaccine.2015.03.011.
   PubMed Web of Science ®Google Scholar
• WHO. Intradermal delivery of vaccines. 2009 [accessed 2022 Mar 20]. https://www.who.int/immunization/programmes_systems/supply_chain/optimize/Intradermal-delivery-vaccines_report_2009-Sept.pdf.
   Google Scholar
• Okayasu H, Sein C, Chang Blanc D, Gonzalez AR, Zehrung D, Jarrahian C, Macklin G, Sutter RW. Intradermal administration of fractional doses of inactivated poliovirus vaccine: a dose-sparing option for polio immunization. J Infect Dis. 2017;216(suppl_1):S161–67. doi:10.1093/infdis/jix038.
   PubMedGoogle Scholar
• Cadorna-Carlos J, Vidor E, Bonnet MC. Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. Int J Infect Dis. 2012;16(2):e110–6. doi:10.1016/j.ijid.2011.10.002.
   PubMed Web of Science ®Google Scholar
• Anand A, Molodecky NA, Pallansch MA, Sutter RW. Immunogenicity to poliovirus type 2 following two doses of fractional intradermal inactivated poliovirus vaccine: a novel dose sparing immunization schedule. Vaccine. 2017;35(22):2993–98. doi:10.1016/j.vaccine.2017.03.008.
   PubMed Web of Science ®Google Scholar
• Bandyopadhyay AS, Gast C, Rivera L, Saez-Llorens X, Oberste MS, Weldon WC, Modlin J, Clemens R, Costa Clemens SA, Jimeno J, et al. Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial. Lancet Infect Dis. 2021;21(4):559–68. doi:10.1016/S1473-3099(20)30555-7.
   PubMed Web of Science ®Google Scholar
• Yu C, Walter M. CADTH Rapid Response Report: Summary with Critical Appraisal. Needleless injectors for the administration of vaccines: areview of clinical effectiveness. Canada: Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020. 33296154. https://pubmed.ncbi.nlm.nih.gov/33296154/
   Google Scholar
• Jaiswal N, Singh S, Agarwal A, Chauhan A, Thumburu KK, Kaur H, Singh M. Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis. Cochrane Database Syst Rev. 2019;12:CD011780. doi:10.1002/14651858.CD011780.pub2.
   PubMedGoogle Scholar
• Hoffman PN, Abuknesha RA, Andrews NJ, Samuel D, Lloyd JS. A model to assess the infection potential of jet injectors used in mass immunisation. Vaccine. 2001;19(28–29):4020–27. doi:10.1016/S0264-410X(01)00106-2.
   PubMed Web of Science ®Google Scholar
• Sweat JM, Abdy M, Weniger BG, Harrington R, Coyle B, Abuknesha RA, Gibbs EP. Safety testing of needle free, jet injection devices to detect contamination with blood and other tissue fluids. Ann N Y Acad Sci. 2000;916:681–82. doi:10.1111/j.1749-6632.2000.tb05361.x.
   PubMed Web of Science ®Google Scholar
• Resik S, Tejeda A, Lago PM, Diaz M, Carmenates A, Sarmiento L, Alemani N, Galindo B, Burton A, Friede M, et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis. 2010;201(9):1344–52. doi:10.1086/651611.
   PubMed Web of Science ®Google Scholar
• Mohammed AJ, AlAwaidy S, Bawikar S, Kurup PJ, Elamir E, Shaban MM, Sharif SM, van der Avoort HG, Pallansch MA, Malankar P, et al. Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med. 2010;362(25):2351–59. doi:10.1056/NEJMoa0909383.
   PubMed Web of Science ®Google Scholar
• Estivariz CF, Jafari H, Sutter RW, John TJ, Jain V, Agarwal A, Verma H, Pallansch MA, Singh AP, Guirguis S, et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: a community-based, randomised controlled trial. Lancet Infect Dis. 2012;12(2):128–35. doi:10.1016/S1473-3099(11)70190-6.
   PubMed Web of Science ®Google Scholar
• Moon SS, Richter-Roche M, Resch TK, Wang Y, Foytich KR, Wang H, Mainou BA, Pewin W, Lee J, Henry S, et al. Microneedle patch as a new platform to effectively deliver inactivated polio vaccine and inactivated rotavirus vaccine. NPJ Vaccines. 2022;7(1):26. doi:10.1038/s41541-022-00443-7.
   PubMed Web of Science ®Google Scholar
• Wei JCJ, Haridass IN, Crichton ML, Mohammed YH, Meliga SC, Sanchez WY, Grice JE, Benson HAE, Roberts MS, Kendall MAF. Space- and time-resolved investigation on diffusion kinetics of human skin following macromolecule delivery by microneedle arrays. Sci Rep. 2018;8(1):17759. doi:10.1038/s41598-018-36009-8.
   PubMedGoogle Scholar
• Edens C, Dybdahl-Sissoko NC, Weldon WC, Oberste MS, Prausnitz MR. Inactivated polio vaccination using a microneedle patch is immunogenic in the rhesus macaque. Vaccine. 2015;33(37):4683–90. doi:10.1016/j.vaccine.2015.01.089.
   PubMed Web of Science ®Google Scholar
• Jeong SY, Park JH, Lee YS, Kim YS, Park JY, Kim SY. The current status of clinical research involving microneedles: a systematic review. Pharmaceutics. 2020;12(11). doi:10.3390/pharmaceutics12111113.
   Web of Science ®Google Scholar
• Adhikari BB, Goodson JL, Chu SY, Rota PA, Meltzer MI. Assessing the potential cost-effectiveness of microneedle patches in childhood measles vaccination programs: the case for further research and development. Drugs RS. 2016;16(4):327–38. doi:10.1007/s40268-016-0144-x.
   PubMed Web of Science ®Google Scholar
• Kolluru C, Gomaa Y, Prausnitz MR. Development of a thermostable microneedle patch for polio vaccination. Drug Deliv Transl Res. 2019;9(1):192–203. doi:10.1007/s13346-018-00608-9.
   PubMed Web of Science ®Google Scholar
• Muller DA, Pearson FE, Fernando GJ, Agyei-Yeboah C, Owens NS, Corrie SR, Crichton ML, Wei JC, Weldon WC, Oberste MS, et al. Inactivated poliovirus type 2 vaccine delivered to rat skin via high density microprojection array elicits potent neutralising antibody responses. Sci Rep. 2016;6:22094. doi:10.1038/srep22094.
   PubMed Web of Science ®Google Scholar
• Fernando GJ, Zhang J, Ng HI, Haigh OL, Yukiko SR, Kendall MA. Influenza nucleoprotein DNA vaccination by a skin targeted, dry coated, densely packed microprojection array (Nanopatch) induces potent antibody and CD8(þ) T cell responses. J Control Release. 2016;237:35–41. doi:10.1016/j.jconrel.2016.06.045.
   PubMed Web of Science ®Google Scholar
• Pearson FE, McNeilly CL, Crichton ML, Primiero CA, Yukiko SR, Fernando GJ, Chen X, Gilbert SC, Hill AV, Kendall MA. Dry-coated live viral vector vaccines delivered by nanopatch microprojections retain long-term thermostability and induce transgene-specific T cell responses in mice. PLoS One. 2013;8(7):e67888. doi:10.1371/journal.pone.0067888.
   PubMed Web of Science ®Google Scholar
• Prow TW, Chen X, Prow NA, Fernando GJ, Tan CS, Raphael AP, Chang D, Ruutu MP, Jenkins DW, Pyke A, et al. Nanopatch-targeted skin vaccination against west Nile virus and chikungunya virus in mice. Small. 2010;6(16):1776–84. doi:10.1002/smll.201000331.
   PubMed Web of Science ®Google Scholar
• Pearson FE, Muller DA, Roalfe L, Zancolli M, Goldblatt D, Kendall MA. Functional anti-polysaccharide IgG titres induced by unadjuvanted pneumococcal-conjugate vaccine when delivered by microprojection-based skin patch. Vaccine. 2015;33(48):6675–83. doi:10.1016/j.vaccine.2015.10.081.
   PubMed Web of Science ®Google Scholar
• Crichton ML, Muller DA, Depelsenaire ACI, Pearson FE, Wei J, Coffey J, Zhang J, Fernando GJP, Kendall MAF. The changing shape of vaccination: improving immune responses through geometrical variations of a microdevice for immunization. Sci Rep. 2016;6:27217. doi:10.1038/srep27217.
   PubMed Web of Science ®Google Scholar
• Crichton ML, Archer-Jones C, Meliga S, Edwards G, Martin D, Huang H, Kendall MA. Characterising the material properties at the interface between skin and a skin vaccination microprojection device. Acta Biomater. 2016;36:186–94. doi:10.1016/j.actbio.2016.02.039.
   PubMed Web of Science ®Google Scholar
• McNeilly CL, Crichton ML, Primiero CA, Frazer IH, Roberts MS, Kendall MA. Microprojection arrays to immunise at mucosal surfaces. J Control Release. 2014;196:252–60. doi:10.1016/j.jconrel.2014.09.028.
   PubMed Web of Science ®Google Scholar
• Raphael AP, Prow TW, Crichton ML, Chen X, Fernando GJ, Kendall MA. Targeted, needle-free vaccinations in skin using multilayered, densely-packed dissolving microprojection arrays. Small. 2010;6(16):1785–93. doi:10.1002/smll.201000326.
   PubMed Web of Science ®Google Scholar
• Raphael AP, Crichton ML, Falconer RJ, Meliga S, Chen X, Fernando GJ, Huang H, Kendall MA. Formulations for microprojection/microneedle vaccine delivery: structure, strength and release profiles. J Control Release. 2016;225:40–52. doi:10.1016/j.jconrel.2016.01.027.
   PubMed Web of Science ®Google Scholar
• Jenkins D, Corrie S, Flaim C, Kendall M. High density and high aspect ratio solid micro-nanoprojection arrays for targeted skin vaccine delivery and specific antibody extraction. RSC Adv. 2012;2(8):3490–95. doi:10.1039/C2RA20153D.
   Web of Science ®Google Scholar
• Meyer BK, Kendall MAF, Williams DM, Bett AJ, Dubey S, Gentzel RC, Casimiro D, Forster A, Corbett H, Crichton M, et al. Immune response and reactogenicity of an unadjuvanted intradermally delivered human papillomavirus vaccine using a first generation Nanopatch™ in rhesus macaques: an exploratory, pre-clinical feasibility assessment. vaccine X. 2019;2(2):100030. doi:10.1016/j.jvacx.2019.100030.
   PubMedGoogle Scholar
• Westdijk J, Brugmans D, Martin J, van’t Oever A, Bakker WAM, Levels L, Kersten G. Characterization and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for inactivated polio vaccines. Vaccine. 2011;29(18):3390–97. doi:10.1016/j.vaccine.2011.02.085.
   PubMed Web of Science ®Google Scholar
• Crichton ML, Ansaldo A, Chen XF, Prow TW, Fernando GJP, Kendall MAF. The effect of strain rate on the precision of penetration of short densely-packed microprojection array patches coated with vaccine. Biomaterials. 2010;31(16):4562–72. doi:10.1016/j.biomaterials.2010.02.022.
   PubMed Web of Science ®Google Scholar
• Depelsenaire ACI, Meliga SC, McNeilly CL, Pearson FE, Coffey JW, Haigh OL, Flaim CJ, Frazer IH, Kendall MAF. Colocalization of cell death with antigen deposition in skin enhances vaccine immunogenicity. J Invest Dermatol. 2014;134(9):2361–70. doi:10.1038/jid.2014.174.
   PubMed Web of Science ®Google Scholar
• Wan Y, Gupta V, Bird C, Pullagurla SR, Fahey P, Forster A, Volkin DB, Joshi SB. Formulation development and improved stability of a combination measles and rubella live-viral vaccine dried for use in the nanopatch(TM) microneedle delivery system. Hum Vaccin Immunother. 2021;17(8):2501–16. doi:10.1080/21645515.2021.1887692.
   PubMed Web of Science ®Google Scholar
• Kumar P, Shukla RS, Patel A, Pullagurla SR, Bird C, Ogun O, Kumru OS, Hamidi A, Hoeksema F, Yallop C, et al. Formulation development of a live attenuated human rotavirus (RV3-BB) vaccine candidate for use in low- and middle-income countries. Hum Vaccin Immunother. 2021;17(7):2298–310. doi:10.1080/21645515.2021.1885279.
   PubMed Web of Science ®Google Scholar
• Kumar P, Pullagurla SR, Patel A, Shukla RS, Bird C, Kumru OS, Hamidi A, Hoeksema F, Yallop C, Bines JE, et al. Effect of formulation variables on the stability of a live, rotavirus (RV3-BB) vaccine candidate using in vitro gastric digestion models to mimic oral delivery. J Pharm Sci. 2021;110(2):760–70. doi:10.1016/j.xphs.2020.09.047.
   PubMed Web of Science ®Google Scholar
• McAdams D, Estrada M, Holland D, Singh J, Sawant N, Hickey JM, Kumar P, Plikaytis B, Joshi SB, Volkin DB, et al. Concordance of in vitro and in vivo measures of non-replicating rotavirus vaccine potency. Vaccine. 2022;40(34):5069–78. doi:https://doi.org/10.1016/j.vaccine.2022.07.017.
   PubMed Web of Science ®Google Scholar
• Hamidi A, Hoeksema F, Velthof P, Lemckert A, Gillissen G, Luitjens A, Bines JE, Pullagurla SR, Kumar P, Volkin DB, et al. Developing a manufacturing process to deliver a cost effective and stable liquid human rotavirus vaccine. Vaccine. 2021;39(15):2048–59. doi:10.1016/j.vaccine.2021.03.033.
   PubMed Web of Science ®Google Scholar
• Falcaro M, Castanon A, Ndlela B, Checchi M, Soldan K, Lopez-Bernal J, Elliss-Brookes L, Sasieni P. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet. 2021;398(10316):2084–92. doi:10.1016/S0140-6736(21)02178-4.
   PubMed Web of Science ®Google Scholar
• Lei J, Ploner A, Elfstrom KM, Wang J, Roth A, Fang F, Sundstrom K, Dillner J, Sparen P. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020;383(14):1340–48. doi:10.1056/NEJMoa1917338.
   PubMed Web of Science ®Google Scholar
• WHO. Human papillomavirus (HPV) and cervical cancer. 2022 [accessed 2022 Sept 5]. https://www.who.int/news-room/fact-sheets/detail/cervical-cancer.
   Google Scholar
• Parashar UD, Johnson H, Steele AD, Tate JE. Health impact of rotavirus vaccination in developing countries: progress and way forward. Clin Infect Dis. 2016;62 Suppl 2:S91–5. doi:10.1093/cid/civ1015.
   PubMed Web of Science ®Google Scholar
• Tate JE, Burton AH, Boschi-Pinto C, Parashar UD, World Health Organization-Coordinated Global Rotavirus Surveillance N. Global, regional, and national estimates of rotavirus mortality in children <5 years of age, 2000-2013. Clin Infect Dis. 2016;62(Suppl 2):S96–105. doi:10.1093/cid/civ1013.
   PubMed Web of Science ®Google Scholar
• Drain PK, Nelson CM, Lloyd JS. Single-dose versus multi-dose vaccine vials for immunization programmes in developing countries. Bull World Health Organ. 2003;81:726–31.
   PubMed Web of Science ®Google Scholar
• Jerajani K, Wan Y, Hickey JM, Kumru OS, Sharma N, Pullagurla SR, Ogun O, Mapari S, Whitaker N, Brendle S, et al. Analytical and preformulation characterization studies of human papillomavirus virus-like particles to enable quadrivalent multi-dose vaccine formulation development. J Pharm Sci. 2022. doi:10.1016/j.xphs.2022.07.019.
   Web of Science ®Google Scholar
• Sharma N, Jerajani K, Wan Y, Kumru OS, Pullagurla SR, Ogun O, Mapari S, Brendle SA, Christensen ND, Batwal S, et al. Multi-dose formulation development for a quadrivalent human papillomavirus virus-like particle-based vaccine: part II- accelerated and real-time stability studies. 2022. doi:10.1016/j.xphs.2022.11.021.
   Google Scholar
• Kirkwood CD, Ma L-F, Carey ME, Steele AD. The rotavirus vaccine development pipeline. vaccine. 2019;37(50):7328–35. doi:https://dx.doi.org/10.1016/j.vaccine.2017.03.076.
   PubMed Web of Science ®Google Scholar
• Witte D, Handley A, Jere KC, Bogandovic-Sakran N, Mpakiza A, Turner A, Pavlic D, Boniface K, Mandolo J, Ong DS, et al. Neonatal rotavirus vaccine (RV3-BB) immunogenicity and safety in a neonatal and infant administration schedule in Malawi: a randomised, double-blind, four-arm parallel group dose-ranging study. Lancet Infect Dis. 2022;22(5):668–78. doi:10.1016/S1473-3099(21)00473-4.
   PubMed Web of Science ®Google Scholar
• Pullagurla SR, Kumar P, Ogun O, Kumru OS, Hamidi A, Hoeksema F, Yallop C, Bines JE, Volkin DB, Joshi SB. Modeling the long-term 2-8 degrees C stability profiles of a live, rotavirus vaccine candidate (RV3-BB) in various liquid formulations via extrapolations of real-time and accelerated stability data. Biologicals. 2022;75:21–28. doi:10.1016/j.biologicals.2021.12.001.
   PubMed Web of Science ®Google Scholar
• Cates JE, JE T, Parashar U. Rotavirus vaccines: progress and new developments. Expert Opin Biol Ther. 2021. doi:10.1080/14712598.2021.1977279.
   PubMed Web of Science ®Google Scholar
• Debellut F, Pecenka C, Hausdorff WP, Clark A. Potential impact and cost-effectiveness of injectable next-generation rotavirus vaccines in 137 LMICs: a modelling study. Hum Vaccin Immunother. 2022;18(1):2040329. doi:10.1080/21645515.2022.2040329.
   PubMed Web of Science ®Google Scholar
• Kyle Lakatos DM, White JA, White JA, Chen D. Dexiang Chen, Formulation and preclinical studies with a trivalent rotavirus P2-VP8 subunit vaccine. Hum Vaccin Immunother. 2020;16(8):1957–68. doi:10.1080/21645515.2019.1710412.
   PubMed Web of Science ®Google Scholar
• Forman R, Shah S, Jeurissen P, Jit M, Mossialos E. COVID-19 vaccine challenges: what have we learned so far and what remains to be done? Health Policy (New York). 2021;125(5):553–67. doi:10.1016/j.healthpol.2021.03.013.
   PubMed Web of Science ®Google Scholar
• Bajoria S, Kaur K, Kumru OS, Van Slyke G, Doering J, Novak H, Rodriguez Aponte SA, Dalvie NC, Naranjo CA, Johnston RS, et al. Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants. Hum Vaccin Immunother. 2022;18(5):2079346. doi:10.1080/21645515.2022.2079346.
   PubMed Web of Science ®Google Scholar